Business Context and Reporting Period
This Form 8-K reports on the Special Meeting of Stockholders held by Tivic Health Systems, Inc. (trading symbol: TIVC) on January 31, 2025. The filing details the voting results regarding corporate governance proposals. Note: The metadata provided in the request references "Valion Bio, Inc.," but the filing text explicitly identifies the registrant as Tivic Health Systems, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate actions and voting results rather than financial performance.
Material Changes and Voting Results
At the record date of December 20, 2024, the Company had 9,467,327 shares of common stock outstanding. Approximately 34.9% of outstanding shares were represented at the Special Meeting, establishing a quorum. Stockholders approved two key proposals:
- Proposal No. 1 (Reverse Stock Split): Stockholders granted the Board discretionary authority to effect a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-30. This authority is valid for twelve months from the meeting date without further stockholder approval.
- Votes For: 3,028,943
- Votes Against: 243,254
- Abstentions: 33,240
- Proposal No. 2 (Adjournment): Stockholders authorized the Board to adjourn the meeting to solicit additional proxies if necessary.
- Votes For: 3,063,516
- Votes Against: 210,617
- Abstentions: 31,304
The Board did not exercise the option to adjourn the meeting as Proposal No. 1 was approved.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future operations, or a discussion of risks and contingencies beyond the standard incorporation by reference of the Definitive Proxy Statement (Schedule 14A) filed on January 3, 2025.
Investor Verification Checklist
- Verify the exact reverse stock split ratio the Board intends to implement within the next twelve months.
- Review the Definitive Proxy Statement (Schedule 14A) filed on January 3, 2025, for detailed rationale and risk factors associated with the reverse split.
- Monitor future filings for the official announcement of the effective date and ratio of the reverse stock split.
- Confirm the current share count and trading status on Nasdaq following the implementation of the split.